Recently, the 2019 Top 100 Chinese Pharmaceutical Industry Rankings were grandly released, with Shanghai RAAS ranking 11th on the biopharmaceutical enterprise list. It has been on the list for two consecutive years, steadily advancing by four places compared to last year.
It is reported that this selection focuses on the innovation driving force and professional promotion force of pharmaceutical industrial enterprises. The innovation driving force is mainly judged from the comprehensive indicators of enterprise R&D investment, while the professional promotion force is mainly defined by the quantitative data of the terminal determined by the final selection needs of clinicians and patients. Finally, the exclusive three terminal six market terminal data of MiniMed is used for quantitative analysis.The final list of "2019 China's Top 100 Pharmaceutical Industry Series" is expected to be awarded at the "2020 National Pharmacy Week and China's Top 100 Pharmaceutical Industry Annual Meeting, China Pharmaceutical Internet Economic Annual Meeting" held in Yunnan from August 25th to 28th, 2020.
Shanghai RAAS was established in 1988 and listed in 2008. It mainly produces blood products and is one of the few domestic manufacturers that can export blood products.Shanghai RAAS defines the mission of the blood products business as "a cause for the heart and a passion for the country", connecting the hearts of plasma donors and patients through products, and paying equal attention to both internal and external cultivation, emphasizing both morality and technology, keeping the original intention in mind, forming positive energy interaction and resonance of life;actively adapting to the trend and changing with the times, continuing to adhere to openness and inclusiveness, and transmitting positive energy in the blood products industry.